Nucleic acid probes immobilized on polystyrene surfaces |
| We claim: 1. An article of manufacture for use in a solution phase nucleic acid sandwich ... |
|
High molecular weight polymer-based prodrugs |
| The present invention addresses the shortcomings described above. In one aspect of the invention, ... |
|
Non-antigenic branched polymer conjugates |
| OF THE INVENTION 1. POLYMER SUBSTITUENTS AND FORMULA (I) DEFINED The activated branched polymers ... |
|
Substantially pure histidine-linked protein polymer conjugates |
| In one aspect, the present invention includes substantially pure protein-polymer conjugates. The ... |
|
Crosslinked polymer compositions and methods for their use |
| The present invention discloses a crosslinked polymer composition comprising a first synthetic ... |
|
Conjugation of polypeptides |
| OF THE INVENTION It is the object of the invention to provide polypeptide conjugates with reduced ... |
|
High molecular weight polymer-based prodrugs |
| OF THE INVENTION A. THE PRODRUGS In most aspects of the invention, the prodrug compositions of the ... |
|
Non-antigenic amine derived polymers and polymer conjugates |
| In one aspect of the invention, there are provided amine-based polymer intermediates having the ... |
|
|
Peptide-containing polyethylene glycol derivatives and application thereof
| Details |
Inventors: Tsukada, Yoshihisa; Orikasa, Atsushi;
Assignee: Fuji Photo Film Co., Ltd. (Kanagawa, JP)
Primary Examiner: Griffin; Ronald W.
Assistant Examiner:
Attorney, Agent or Firm: Sughrue, Mion, Zinn, Macpeak & Seas
A peptide-containing polyethylene glycol derivative represented by the following general formula [I] or [II]: ##STR1## wherein each R.sup.1 independently represents a peptide residue represented by the following general formula [IIIa] or [IIIa]: -([X]-Arg-Gly-Asp-[Y]).sub.m -Z [IIIa] ([X]-Glu-Ile-Leu-Asp-val-Pro-Ser-Thr-[Y]).sub.m (IIIb) wherein Arg, Gly, Asp, Glu, Ile, Leu, val, Pro, Ser and Thr represent arginine, glycine, aspartic acid, glutamic acid, isoleucine, leucine, valine, proline, serine and threonine residue respectively; [X] and [Y] each represents an amino acid or peptide residue which may be present or absent; n is an integer ranging from 1 to 150; m is an integer ranging from 1 to 5 and Z represents --OH or --NH.sub.2, provided that the peptide residue [IIIb] and the triazine ring is bonded at the position of [X] (if [X] is absent, at the position of Glu) or [Y] (or if [Y] is absent, at the position of Thr) or a salt thereof. The compound is useful as an effective ingredient of a composition for inhibiting adhesion of animal cells comprising or for inhibiting coagulation/cohesion of blood platelets. |
|
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will hereinafter be explained in more detail. The peptide-containing polyethylene glycol derivatives of the present invention are represented by the following general formula [I] or [II]; ##STR3## In the formulae [I] and [II], ionic groups present in the molecule may form salts with appropriate counter ions, and each R. sup. 1 independently represents a peptide residue represented by the following general formula [IIIa] or [IIIb]; -([X]-Arg-Gly-Asp-[Y]). sub. m -Z [IIIa] ([X]-Glu-Ile-Leu-Asp-Val-Pro-Ser-Thr-[Y]). sub. m [IIIb](SEQ ID NO: 1), as ([X]-[SEQ ID NO:1)-[Y]). sub. m In the formulae [IIIa] and [IIIb], Arg, Gly, Asp, Glu, Ile, Leu, Val, Pro, Ser and Thr represent arginine, glycine, aspartic acid, glutamic acid, isoleucine, leucine, valine, proline, serine and threonine residues respectively. [X] and [Y] independently represents an amino acid or peptide residue which may be independently present or absent. If one or both of them are present, they preferably represent an amino acid residue selected from the group consisting of serine, glycine, valine, asparagine, proline, cysteine and threonine residues or a peptide residue constituted by the foregoing amino acid residues, and the number of amino aci residues constituting the peptide residue is preferably 2 or 3. In particular, [X] preferably represents a glycine residue and [Y] preferably represents a serine residue or a serine-proline peptide residue or preferably both [X] and [Y] are absent. The number of n is an integer ranging from 1 to 150, preferably 5 to 120, m is an integer ranging from 1 to 5, preferably 1 to 3, and Z represents --OH or --NH. sub. 2. The peptide residue [IIIb] is bonded to the triazine ring at the position [X] (or if [X] is absent, at the position of Glu residue) or [Y] (or if [Y] is absent, at the position of Thr residue). As the salts of the compounds of the present invention, there may preferably be mentioned, for instance, sodium, potassium, ammonium and magnesium salts as well as hydrochlorides, sulfates, nitrates and acetates
|
| Related patents |
|
|
Modified HIL-6
OF THE INVENTION Described below is the chemical modification with PEG of at least one amino group of polypeptides possessing IL-6 activities. This modification results ...
|
|
|
Construction of geometrical objects from polynucleotides
By means of the present invention, DNA, RNA and similar polymers may be produced by synthesizing a double stranded segment, preferably with a loop at one end, cleaving ...
|
|
|
Starburst conjugates
In its broadest aspect, the present invention is directed to polymer conjugate materials comprising dense star polymers or starburst polymers associated with desired ...
|
|
|
Intermediates for providing functional groups on the 5' end of oligonucleotides
We claim: 1. A partially protected alcohol of the formula: ##STR10## wherein Y.sup.1 is selected from dimethoxytrityl, monomethoxytrityl, trityl or pixyl, Y.sup.2 is ...
|
|
|
Antiviral polynucleotide conjugates
OF THE INVENTION The present invention provides polynucleotide conjugates characterized by the properties of ligand binding and enhanced stability. In the present ...
|
|
|
Azlactone activated polyalkylene oxides conjugated to biologically active nucleophiles
OF THE PREFERRED EMBODIMENT The azlactone activated polyalkylene oxides of the present invention are preferably prepared from polyalkylene oxides that are soluble in ...
|
|
|
Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
INCLUSIVE OF PREFERRED EMBODIMENTS We have discovered that linear block copolymers comprising blocks of poly(alkylene oxide) (PAGs) and peptides attached via --CH.sub.2 ...
|
|
|
Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
The present invention provides for compounds having the formula: ##STR1## wherein R.sub.1 is selected from the group consisting of an N-benzotriazole group, an N-2-...
|
|
|
Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
OF THE INVENTION The following examples are given to illustrate the invention, but should not be considered in limitation of the invention: Example 1--Synthesis of CH....
|
|
|
Polyoxypropylene/polyoxyethylene copolmers with improved biological activity
Although the prior art preparations of polyoxypropylene/polyoxyethylene block copolymers may have been suitable for industrial uses, it has been determined that the ...
|
|
|